drugset / Trial / NCT04632927

Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment

NCT04632927

Phase 3 Completed 119 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to compare the safety and efficacy of secukinumab and ustekinumab in patients with active psoriatic arthritis who showed failure to previous TNFα-inhibitor treatment

Timeline

Start
2020-12-21
Primary completion
2024-10-22
Completion
2024-10-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Secukinumab Monoclonal antibody Subcutaneous
Subject Ustekinumab Monoclonal antibody

Indications